How NCCN Guidelines Help Inform Treatment Selection in EGFR-Mutated NSCLC

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, examine how National Comprehensive Cancer Network (NCCN) Guidelines inform frontline treatment decisions in EGFR-mutated non–small cell lung cancer. Raez explains how multiple preferred, category 1 regimens require clinicians to interpret nuanced differences in trial design, efficacy outcomes, and toxicity data. Spira also addresses recommendations for patients with brain metastases and how available data support the use of CNS-active combination strategies in this high-risk subgroup.